Health news and commentary gathered by MedPage Today staff
— Health news and commentary gathered by MedPage Today staff
August 25, 2026
• 2 min read
Note that some links may require registration or subscription.
Vitruvias Therapeutics issued a nationwide recall of one lot of thyroid tablets USP 30 mg, used to treat hypothyroidism, due to their potential to be superpotent, according to an announcement on the FDA web site.
FDA recalls Vitruvias thyroid tablets after testing finds potential ‘superpotency’; here’s who faces greater risk
Vitruvias Therapeutics recalls 30 mg thyroid tablets over superpotency
Vitruvias Therapeutics, Inc. Issues Nationwide Recall of One Lot of Thyroid Tablets, USP 30 mg Due to Potential Super Potency
News and commentary from the endocrinology world
Vitruvias Therapeutics has announced a voluntary recall of its thyroid tablets after tests indicated the potential for…
The Auburn, Alabama company recalled one lot of its 30 mg thyroid tablets after testing confirmed they could be stronger than…
Vitruvias Therapeutics, Inc. Issues Nationwide Recall of One Lot of Thyroid Tablets, USP 30 mg Due to Potential Super Potency
A nationwide recall was issued for this common thyroid medication. See the recalled products.
The FDA has recalled levothyroxine sodium nationwide due to potency standard concerns. This medication is used to treat…
